These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22805048)

  • 1. Structure-based design technology contour and its application to the design of renin inhibitors.
    Ishchenko A; Liu Z; Lindblom P; Wu G; Jim KC; Gregg RD; Claremon DA; Singh SB
    J Chem Inf Model; 2012 Aug; 52(8):2089-97. PubMed ID: 22805048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
    Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
    J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo drug design using multiobjective evolutionary graphs.
    Nicolaou CA; Apostolakis J; Pattichis CS
    J Chem Inf Model; 2009 Feb; 49(2):295-307. PubMed ID: 19434831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
    Lorthiois E; Breitenstein W; Cumin F; Ehrhardt C; Francotte E; Jacoby E; Ostermann N; Sellner H; Kosaka T; Webb RL; Rigel DF; Hassiepen U; Richert P; Wagner T; Maibaum J
    J Med Chem; 2013 Mar; 56(6):2207-17. PubMed ID: 23425156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors.
    Moitessier N; Therrien E; Hanessian S
    J Med Chem; 2006 Oct; 49(20):5885-94. PubMed ID: 17004704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
    Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
    Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor flexibility in de novo ligand design and docking.
    Alberts IL; Todorov NP; Dean PM
    J Med Chem; 2005 Oct; 48(21):6585-96. PubMed ID: 16220975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards structure-based protein drug design.
    Zhang C; Lai L
    Biochem Soc Trans; 2011 Oct; 39(5):1382-6, suppl 1 p following 1386. PubMed ID: 21936819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
    Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
    Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational approach to de novo discovery of fragment binding for novel protein states.
    Konteatis ZD; Klon AE; Zou J; Meshkat S
    Methods Enzymol; 2011; 493():357-80. PubMed ID: 21371598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico fragment-based discovery of DPP-IV S1 pocket binders.
    Rummey C; Nordhoff S; Thiemann M; Metz G
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1405-9. PubMed ID: 16321524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations.
    Rich DH; Bursavich MG; Estiarte MA
    Biopolymers; 2002; 66(2):115-25. PubMed ID: 12325161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
    Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
    J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.